The Law Offices of Frank R. Cruz announces an investigation of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) on behalf of investors concerning the Company’s possible violations of federal securities laws.

What Is The Investigation About?
On July 27, 2026, the US Food and Drug Administration released briefing documents ahead of its advisory committee meeting with Capricor regarding the Company’s cell ​therapy for a heart condition related to Duchenne muscular dystrophy.

Among other things, the briefing documents take issue with the manner in which Capricor measured results after the therapy’s late-stage trial ended, stating the “FDA does not ​consider the conversion of raw change to percent change and then back to raw change ​to have been scientifically justified, as it adds complexity and reduces accuracy.” The briefing documents conclude that, among other things, “the benefit-risk assessment for deramiocel appears unfavorable in the absence of evidence of effectiveness.”

Cantor Fitzgerald analyst Kristen Kluska published an investor note on the issue, stating the FDA’s “briefing documents paint an ugly picture” and “raise several concerns and make allegations about the integrity of data collecting.”

On this news, shares of Capricor stock declined as much as $12.29, or 62.39%, during intraday trading on July 27, 2026.